LivaNova PLC Reports Fourth Quarter And Full-Year 2016 Results
LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the fourth quarter and full year ended December 31, 2016.
For the fourth quarter of 2016, worldwide sales were $311 million, a decrease of 2.3 percent on a reported basis and a decrease of 1.6 percent on a constant-currency basis, as compared to the previous year. On a U.S. Generally Accepted Accounting Principles (GAAP) basis, fourth quarter 2016 loss per share was ($0.61). Fourth quarter 2016 adjusted diluted earnings per share were $0.85. For full-year 2016, worldwide sales were $1.2 billion, an increase of 0.8 percent on a reported basis and increase of 1.0 percent on a constant-currency basis, as compared to the previous year. On a GAAP basis, full-year 2016 loss per share was ($1.29). Full-year 2016 adjusted diluted earnings per share were $3.05.
For the fourth quarter of 2016, worldwide sales were $311 million, a decrease of 2.3 percent on a reported basis and a decrease of 1.6 percent on a constant-currency basis, as compared to the previous year. On a U.S. Generally Accepted Accounting Principles (GAAP) basis, fourth quarter 2016 loss per share was ($0.61). Fourth quarter 2016 adjusted diluted earnings per share were $0.85. For full-year 2016, worldwide sales were $1.2 billion, an increase of 0.8 percent on a reported basis and increase of 1.0 percent on a constant-currency basis, as compared to the previous year. On a GAAP basis, full-year 2016 loss per share was ($1.29). Full-year 2016 adjusted diluted earnings per share were $3.05.